Satsuma Pharmaceuticals and SNBL to Present Five STS101 Abstracts at American Headache Society's 66th Meeting

Satsuma Pharmaceuticals, Inc., a biopharmaceutical company in the late stages of development, is making significant strides with its novel migraine treatment, STS101. This innovative product, a nasal powder formulation of dihydroergotamine (DHE), is currently awaiting regulatory approval from the U.S. Food and Drug Administration (FDA). Satsuma, in conjunction with its parent company Shin Nippon Biomedical Laboratories, Ltd. (SNBL), announced that five abstracts detailing the efficacy and safety of STS101 from Phase 3 clinical studies have been selected for presentation at the American Headache Society's (AHS) 66th Annual Scientific Meeting. This event will take place from June 13 to June 16, 2024, at the Marriott Marquis San Diego Marina in San Diego, California, and also offers a virtual attendance option. Full abstracts are available on the AHS website and will be published in the journal Headache®.

STS101 stands out as a novel therapeutic product designed for the acute treatment of migraine. This nasal powder formulation of DHE is delivered using Satsuma's proprietary nasal device, ensuring quick and convenient self-administration. The unique formulation of STS101 has demonstrated rapid absorption, quick achievement of high plasma DHE concentrations, sustained plasma levels over time, and low dose-to-dose variability, offering significant advantages over existing treatments.

Satsuma Pharmaceuticals operates from its headquarters in Research Triangle Park, North Carolina. It is a wholly-owned subsidiary of SNBL, a leading contract research organization (CRO) that was established in Kagoshima, Japan, in 1957. SNBL has a long-standing mission to support drug development and enhance medical technology to alleviate human suffering. The company's extensive portfolio includes providing comprehensive services and solutions for drug discovery and development to pharmaceutical companies, biotech ventures, universities, and research institutions globally.

SNBL's Translational Research Business focuses on drug discovery, particularly in the development and out-licensing of proprietary intranasal drug delivery technologies and devices. Additionally, SNBL operates the Medipolis Business, which utilizes 900 acres of land in Ibusuki-City, Kagoshima prefecture, for local economic promotion and environmental conservation. This includes geothermal power generation and hospitality services, such as a Proton Center for cancer patients, aimed at improving quality of life and well-being.

While SNBL contributes significantly to drug development and medical advancements, it is also engaged in activities that promote environmental sustainability and local economic development. Through these efforts, SNBL aims to enhance overall happiness and quality of life for communities.

The announcement from Satsuma Pharmaceuticals and SNBL underscores their commitment to advancing medical treatments and highlights the promising potential of STS101 for migraine sufferers. The forthcoming presentations at the AHS Annual Scientific Meeting will provide further insights into the clinical benefits and safety of this novel treatment, potentially paving the way for its approval and use.

In summary, Satsuma Pharmaceuticals, with the backing of SNBL, is on the cusp of delivering a new, effective treatment for acute migraine, emphasizing rapid relief and ease of use. The selection of their research for presentation at a prestigious medical conference reflects the significant impact STS101 could have on migraine management.